ATRC News and Press, AtriCure Inc. From 02/06/20

BTIG Research has restarted coverage on the following: More news on: Abbott Laboratories, Abiomed, Inc., AtriCure, Inc., Healthcare stocks news, , Read more ...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming SVB Leerink 9 th Annual Global Healthcare Conference in New York Cit...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2019 financial results on Tuesday, February 18, 2020. AtriCure will host a ...

AtriCure (NASDAQ: ATRC ) expects $61.3M in Q4 revenue (+16% Y/Y) with U.S. revenue of $49.5M and $11.8M in international sales. More news on: AtriCure, Inc., Healthcare stocks news, Read more ...

  AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced preliminary financial results for the fourth quarter and full year 2019 and provided 2020 financial guidance. Preliminary, unau...

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the successful completion of patient enrollment in the aMAZE™ clinical trial. In addition, the company announced that it has rece...

The SPDR S&P 500 Trust's (SPY) rally to new highs has been a boon to big-cap investors, but the Russell 2000 has yet to eclipse its 2018 highs, and that's left small-cap investors envious. Fortunately, small caps' under-performance may not last much longer. Over the past decade, the Russel...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that the company will be participating in the upcoming 38th Annual JP Morgan Healthcare Conference in San Francisco. AtriCure&...

AtriCure, Inc. (Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Karen Prange and Daniel Florin have been named to its Board of Directors. Ms. Prange was most recently Executive Vice Presid...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that the company will be participating in the upcoming Piper Jaffray 31 st Annual Healthcare Conference in New York City. Atr...